Tags : BRAF V600 Mutation-Positive Advanced Melanoma

Roche Reports Results of Triple Combination Regimen in P-III IMspire150

Tuba Khan December 13, 2019

Shots: The P-III IMspire150 study involves assessing of Tecentriq (atezolizumab) + Cotellic (cobimetinib) + Zelboraf (vemurafenib) vs PBO+ Cotellic + Zelboraf in patients with previously untreated BRAF V600 mutation-positive advanced […]readmore

Tags : BRAF V600 Mutation-Positive Advanced Melanoma

Roche Reports Results of Triple Combination Regimen in P-III IMspire150

Latest Posts

PharmaShots Weekly Snapshots (November 15 – 19, 2021)

Jazz’ Sunosi (solriamfetol) Receives NICE Recommendation for the Treatment of Excessive Daytime Sleepiness Caused by Narcolepsy

Antengene’s Selinexor (ATG-010) Receives NMPA’s IND Approval for P-I/II SWATCH Study to Treat Non-Hodgkin Lymphoma

Daiichi Sankyo Reports Results of Quizartinib in P-III QuANTUM-First Trial for the Treatment of FLT3-ITD Positive AML

Company

Tags : BRAF V600 Mutation-Positive Advanced Melanoma

Roche Reports Results of Triple Combination Regimen in P-III IMspire150

Latest Posts

PharmaShots Weekly Snapshots (November 15 – 19, 2021)

Jazz’ Sunosi (solriamfetol) Receives NICE Recommendation for the Treatment of Excessive Daytime Sleepiness Caused by Narcolepsy

Antengene’s Selinexor (ATG-010) Receives NMPA’s IND Approval for P-I/II SWATCH Study to Treat Non-Hodgkin Lymphoma

Daiichi Sankyo Reports Results of Quizartinib in P-III QuANTUM-First Trial for the Treatment of FLT3-ITD Positive AML

Categories

Related Topics

Company